Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating

Archives of Iranian Medicine

Volumn 17, Issue 7, 2014, Pages 466-470

  Jafari, Elham ^a   Vahedi, Homayoon ^a,b   Merat, Shahin ^a,b   Momtahen, Shabnam ^a   Riahi, Aina ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Masoud Laboratory   (Iran)

Author keywords

Adults; Bloating; IBS; Iran; Probiotic

Indexed keywords

LA 5; LACTISBB 12; PLACEBO; PROBIO TEC; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOATING; BORBORYGMI; CONTROLLED STUDY; DEFECATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; IRAN; IRRITABLE COLON; LACTOSE INTOLERANCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; STOMACH DISTENSION; VISUAL ANALOG SCALE; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRAN; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PROBIOTICS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904196386     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. Journal of Managed Care Pharmacy. JMCP. 2004; 10(4): 299-309.
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clinical gastroenterology and Hepatology: The Official Clinical Practice Journal of The American Gastroenterological Association. 2012; 10(7): 712-721.
3. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014; 6: 71-80.
4. Jahangiri P, Jazi MS, Keshteli AH, Sadeghpour S, Amini E, Adibi P. Irritable Bowel Syndrome in Iran: SEPAHAN Systematic Review No. 1. International Journal of Preventive Medicine. 2012; 3(suppl 1): 1-9.
5. Vahedi H, Ansari R, Mir-Nasseri MM, Jafari E. Irritable bowel syndrome: A review article. Middle East Journal of Digestive Diseases. 2010; 2(2): 66-77.
6. Roshandel D, Rezailashkajani M, Shafaee S, Zali MR. A cost analysis of functional bowel disorders in Iran. International Journal of Colorectal Disease. 2007; 22(7): 791-799.
7. Lacy BE, Weiser K, De Lee R. The treatment of irritable bowel syndrome. Therapeutic Advances in Gastroenterology. 2009; 2(4): 221-238.
8. JMJ HRHIv. Probiotics: A general view. In:Lactic Acid Bacteria in Health and Disease. London: Elsevior; 1992.
9. Barbara G, Zecchi L, Barbaro R, Cremon C, Bellacosa L, Marcellini M, et al. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. Journal of Clinical Gastroenterology. 2012; 46 (suppl 5): 52-55.
10. Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology. 2011; 141(2): 599-609.
11. Diaz Heijtz R, Wang S, Anuar F, Qian Y, Bjorkholm B, Samuelsson A, et al. Normal gut microbiota modulates brain development and behavior. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(7): 3047-3052.
12. Matricon J, Meleine M, Gelot A, Piche T, Dapoigny M, Muller E, et al. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2012; 36(11-12): 1009-1031.
13. Spiller R. Review article: Probiotics and prebiotics in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2008; 28(4): 385-396.
14. Walker WA. Mechanisms of action of probiotics. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008; 46 (suppl 2): 87-91
15. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterology. 2009; 9: 15.
16. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World Journal of Gastroenterology (WJG). 2008; 14(17): 2650-2661.
17. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PloS One. 2012; 7(4): e34938.
18. Maxton DG, Morris JA, Whorwell PJ. Ranking of symptoms by patients with the irritable bowel syndrome. BMJ. 1989; 299(6708): 1138.
19. Chang L, Lee OY, Naliboff B, Schmulson M, Mayer EA. Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. Am J Gastroenterol. 2001 Dec; 96(12): 3341-3347.
20. Sadre M, Karbasi K. Lactose intolerance in Iran. The American Journal of Clinical Nutrition. 1979; 32(9): 1948-1954.
21. Bohmer CJ, Tuynman HA. The effect of a lactose-restricted diet in patients with a positive lactose tolerance test, earlier diagnosed as irritable bowel syndrome: a 5-year follow-up study. European Journal of Gastroenterology & Hepatology. 2001; 13(8): 941-944.
22. Levri KM, Ketvertis K, Deramo M, Merenstein JH, D'Amico F. Do probiotics reduce adult lactose intolerance? A systematic review. The Journal of Family Practice. 2005; 54(7): 613-620.
23. Almeida CC, Lorena SL, Pavan CR, Akasaka HM, Mesquita MA. Beneficial effects of long-term consumption of a probiotic combination of Lactobacillus caseiShirota and Bifidobacteriumbreve Yakult may persist after suspension of therapy in lactose-intolerant patients. Nutrition in Clinical Practice: Official Publication of the American Society for Parenteral andEnteral Nutrition. 2012; 27(2): 247-251.
24. Bengtsson M, Ohlsson B, Ulander K. Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS). BMC Gastroenterol. 2007; 7: 16.
25. Bengtsson M, Hammar O, Mandl T, Ohlsson B. Evaluation of gastrointestinal symptoms in different patient groups using the visual analogue scale for irritable bowel syndrome (VAS-IBS). BMC Gastroenterol. 2011; 11: 122. doi: 10.1186/1471-230X-11-122.
26. Ortiz-Lucas M, Tobias A, Saz P, Sebastián JJ. Effects of probiotic species on irritable bowel syndrome symptoms: a bring up to date metaanalysis. RevEsp Enferm Dig. 2013; 105(1): 19-36.
27. Vahedi H, Merat S, Momtahen S, Kazzazi AS, Ghaffari N, Olfati G, et al. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2008; 27(8): 678-684.
28. Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Alimentary Pharmacology & Therapeutics. 2005; 22(5): 381-385.
29. Dorn SD, Kaptchuk TJ, Park JB, Nguyen LT, Canenguez K, Nam BH, et al. A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterology andMotility: The Official Journal of the European Gastrointestinal Motility Society. 2007; 19(8): 630-637.
30. Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2010; 32(2): 144-158.
31. Saberi-Firoozi M, Khademolhosseini F, Mehrabani D, Yousefi M, Salehi M, Heidary ST. Subjective lactose intolerance in apparently healthy adults in southern Iran: Is it related to irritable bowel syndrome? Indian Journal of Medical Sciences. 2007; 61(11): 591-597.
32. Adibi P, Mirshahzadeh P, Sadeghizadeh A. Dairy intolerance syndrome in Iranian young adult. Journal of research in medical sciences. The official journal of Isfahan University of Medical Sciences. 2009; 14(6): 357-366.
33. Hong KS, Kang HW, Im JP, Ji GE, Kim SG, Jung HC, et al. Effect of probiotics on symptoms in korean adults with irritable bowel syndrome. Gut and Liver. 2009; 3(2): 101-107.
34. Mangalat N, Liu Y, Fatheree NY, Ferris MJ, Van Arsdall MR, Chen Z, et al. Safety and tolerability of Lactobacillus reuteri DSM 17938 and effects on biomarkers in healthy adults: results from a randomized masked trial. PloS One. 2012; 7(9): e43910.